Certara inc   (CERT)
Other Ticker:  
    Sector  Technology    Industry Software & Programming
   Industry Software & Programming
   Sector  Technology
Price: $23.8500 $0.20 0.846%
Day's High: $24.45 Week Perf: -3.52 %
Day's Low: $ 23.79 30 Day Perf: 31.84 %
Volume (M): 1,151 52 Wk High: $ 24.83
Volume (M$): $ 27,439 52 Wk Avg: $18.06
Open: $24.02 52 Wk Low: $10.60

 Market Capitalization (Millions $) 3,904
 Shares Outstanding (Millions) 164
 Employees 1,114
 Revenues (TTM) (Millions $) 336
 Net Income (TTM) (Millions $) 15
 Cash Flow (TTM) (Millions $) 53
 Capital Exp. (TTM) (Millions $) 13

Certara Inc
We expedite medicines to patients by transforming traditional drug research and development using biosimulation software, technology, and services.
Biosimulation is a sophisticated technique that allows virtual trials to be conducted using virtual patients in order to better understand how medications respond in various persons. Throughout drug research and development, biopharmaceutical firms utilize our patented biosimulation software to guide important decisions that not only save substantial time and money but also increase drug safety and efficacy, benefitting millions of lives each year.
We build our biosimulation technology on first principles of biology, chemistry, and pharmacology with proprietary mathematical algorithms that model how medicines and diseases behave in the body. For over two decades, we have honed and validated our biosimulation technology with an abundance of data from scientific literature, lab research, and preclinical and clinical studies. In turn, our customers use biosimulation to conduct virtual trials to answer critical questions, such as: What will be the human response to a drug based on preclinical data? How will other drugs interfere with this new drug? What is a safe and efficacious dose for children, the elderly, or patients with pre-existing conditions? Virtual trials may be used to optimize dosing on populations that are otherwise difficult to study for ethical or logistical reasons, such as infants, pregnant women, the elderly, and cancer patients.
We believe that biosimulation continues to grow in adoption, driven by increasing global regulatory support and advancements in technology. We believe we are well-positioned to capture the significant market opportunity ahead of us. Our growth strategy is to build out the depth and breadth of our scalable, end-to-end biopharmaceutical platform to advance all stages of the continuum, from discovery and development to regulatory submission and market access. We continue to innovate and introduce new functionality and uses of biosimulation and technology-driven solutions. We increasingly integrate the science and data we obtain across this end-to-end platform to inform critical decisions. We further reduce the cost and time of human trials to materially accelerate the speed of development and availability of therapies to patients worldwide. As exciting, new research areas arise, we attract and hire specialized talent and acquire businesses to expand our offerings to address these market opportunities.

With continued innovation in and adoption of our biosimulation software, technology and services, we believe more biopharmaceutical companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.

Biosimulation: Biosimulation is the mathematical modeling of biological processes and systems to simulate how a drug affects the body, how the body affects the drug, how potential doses will affect different patient groups, and how patients will respond under various clinical scenarios. Biosimulation informs every stage of the drug discovery and development process and brings value through:
Identifying potential winners and losers at an earlier stage and allowing programs to “fail faster;”
Streamlining preclinical and clinical studies or eliminating certain ones altogether;
Optimizing dosing for different populations for enhanced safety and efficacy; and
Increasing probability of success and return on R&D, amongst others.
Regulatory Science: Regulatory science is the development and application of scientific methods, tools, and approaches to support regulatory and other policy objectives. Expert management of these processes is critical to drugs receiving regulatory approval and ultimately reaching patients and generating sales. Providers of regulatory technology and expertise drive significant value for biopharmaceutical companies through:
Utilizing best-in-class technology to reduce time-intensive regulatory writing activities and the need for regulatory writing staff;
Managing submission timelines and other requirements of global regulatory agencies;
Generating clear, accurate applications and submissions; and
Developing comprehensive global regulatory strategies, amongst others.
Market Access: To achieve commercial access, sponsors must assess, optimize and persuasively communicate the value of a new therapy, both therapeutic and economic, that stakeholders such as payors and health care providers will accept and act on. Market access services, including real-world evidence and health economics outcomes research, generate value by:
Creating cost and comparative effectiveness models to support pricing and payor reimbursement;
Analyzing payor needs and using economic models to develop contracting strategies that optimize value; and
Collecting and analyzing real-world data for use in market and payor communications, amongst others. We believe that our end-to-end platform is well-positioned to continue benefiting from market trends. In addition to continued growth in our core markets, we expect to capture a broader share of overall biopharmaceutical R&D spend as we continue to innovate and add new solutions to our end-to-end platform.
Our Competitive Strengths
We compete by offering a broad and deep combination of industry-standard biosimulation software and technology-driven services across all stages of the continuum, from discovery and development to regulatory approval and market access. We have cultivated the following competitive strengths for more than two decades:
Our Proprietary, Scalable Biosimulation Software
Our proprietary, scalable biosimulation software, built on first principles integrates biosimulation models, scientific knowledge, and data, which we believe would require years of effort, immense resources, and scarce expertise to duplicate. Our versatile biosimulation software is deployed to public and private cloud networks, on-premises, and data centers. Scientists can run multiple simulation projects on a cloud compute platform or internal clusters. We protect our proprietary technology through intellectual property rights, including copyrights, patents, trade secrets, know-how, and trademarks.

   Company Address: 100 Overlook Center Princeton 8540 NJ
   Company Phone Number: 716-7900   Stock Exchange / Ticker: NASDAQ CERT
   CERT is expected to report next financial results on May 04, 2023.

Customers Net Income fell by CERT's Customers Net Profit Margin grew to

-10.41 %

22.24 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABCL        0.13% 
BRKR        5.05% 
MASS        24.66% 
SDGR        0.91% 
SLP        2.63% 
• View Complete Report

Navios South American Logistics Inc

Although revenue sunk in the financial span closing December 31 2018, the company managed to raise its earnings per share, net profit per share elevated on the another level by 112.5 % to $0.34 per share while Sales sunk by -2.732 % to $175.13 millions, year on year.

Golden Falcon Acquisition Corp

GFX, deterioration in the company behavior all over fourth quarter of 2022 earnings season

The Blank Checks sector researchers continue to analyze the fourth quarter of 2022 results. Presently they monitor operating loss of $-1.182917 millions, from the Golden Falcon Acquisition Corp , as it has not specified any revenue still, for the respective October to December 31 2022 financial reporting period.

Berenson Acquisition Corp I

Berenson Acquisition Corp I announced operating income in the fourth quarter of 2022

As the earnings season of the October to December 31 2022 period goes on, countless entities have announced the respective results. Some of them, have been many constituents of the Blank Checks sector. And now, BACA disclosed operating income of $0.455609 millions, for the financial period closing Dec 31 2022.

Zion Oil And Gas Inc

Working expenses were on the rise at the ZNOG in the fiscal period closing December 31 2022

The shareholders haven't expected any moderations at the business during the the earnings cycle of fiscal October to December 31 2022 period at the Zion Oil And Gas Inc. However, they monitor the Oil And Gas Production company's operating loss which came in at $-48.151 millions, in the same period.

Hall Of Fame Resort And Entertainment Company

The Hotels & Tourism company disclosed sudden reduction in Sales, all along the fourth quarter of 2022 earnings season

For the fourth quarter of 2022 earnings season company posted a deficit per stock of $-0.15 per share compare to $0.10 a year before and advanced deficit from $-0.09 per share from the previous quarter.

Sales receded respectably by -16.157 % to $2.52 millions from $3.01 millions in the similar quarter a year before and sequentially Sales Tumbled by -70.879 % from $8.66 millions.


Certara Inc 's Segments
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

REVRQ's Profile

Stock Price

REVRQ's Financials

Business Description


Charts & Quotes

REVRQ's News


REVRQ's Competitors

Customers & Markets

Economic Indicators

REVRQ's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071